Percentages of CD4+CD161+ and CD4−CD8−CD161+ T Cells in the Synovial Fluid Are Correlated with Disease Activity in Rheumatoid Arthritis

Table 1

Characteristics of rheumatoid arthritis (RA) patients and healthy controls (HC).

Characteristics	HC	RA	SF RA
Number of patients	21	54	17
Age in years, median (IQR)	45.0 (34.0–53.0)	46.5 (36.5–54.8)	47.0 (42.0–54.5)
Female sex, (%)	15 (71.4)	40 (74.1)	13 (76.5)
Disease duration, mo, median (IQR)	na	66.0 (11.8–115.5)	60.0 (19.0–102.0)
Rheumatoid factor positive, (%)	na	38 (70.4%)	12 (70.6%)
Anti-CCP positive, (%)	na	40 (74.1%)	14 (82.4%)
ESR, mm/hour, median (IQR)	na	26.5 (14.8–54.0)	54.0 (25.5–72.0)
CRP, mg/dL, median (IQR)	na	0.6 (0.3–3.6)	3.1
DAS28, median (IQR)	na	4.5 (2.6–5.7)	5.4
Systemic steroids, (%)	na	7 (13.0)	2 (11.8)
NSAIDs, (%)	na	8 (14.8)	3 (17.6)
DMARDs (excluding anti-TNF), (%)	na	43 (79.6)	13 (76.5)
Anti-TNF- therapy, (%)	na	8 (14.8)	3 (17.6)

Values are presented as median (interquartile range) or number (percentage). SF, synovial fluid; IQR, interquartile range; Anti-CCP, anticyclic citrullinated peptide antibodies; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, 28-joint disease activity score; NSAIDs, nonsteroidal anti-inflammatory drugs; DMARDs, disease-modifying antirheumatic drugs; TNF-α, tumor necrosis factor-; na, not applicable. compared to RA patients.